C07C 65/01
Containing hydroxy or o-metal groups
Official title: containing hydroxy or O-metal groups
C07C65/01 (Containing hydroxy or o-metal groups) appears on 597 US grants and 531 published applications in this corpus.
Search patents in C07C- Granted patents
- 597
- Published applications
- 531
- Assignees
- 396
- Inventors
- 1,535
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 12 | 0 |
| 1978 | 5 | 0 |
| 1979 | 6 | 0 |
| 1980 | 5 | 0 |
| 1981 | 4 | 0 |
| 1982 | 3 | 0 |
| 1983 | 1 | 0 |
| 1984 | 6 | 0 |
| 1985 | 5 | 0 |
| 1986 | 4 | 0 |
| 1987 | 9 | 0 |
| 1988 | 9 | 0 |
| 1989 | 14 | 0 |
| 1990 | 11 | 0 |
| 1991 | 14 | 0 |
| 1992 | 18 | 0 |
| 1993 | 9 | 0 |
| 1994 | 3 | 0 |
| 1995 | 7 | 0 |
| 1996 | 17 | 0 |
| 1997 | 10 | 0 |
| 1998 | 14 | 0 |
| 1999 | 13 | 0 |
| 2000 | 12 | 0 |
| 2001 | 14 | 1 |
| 2002 | 7 | 11 |
| 2003 | 10 | 6 |
| 2004 | 9 | 15 |
| 2005 | 4 | 8 |
| 2006 | 4 | 9 |
| 2007 | 3 | 15 |
| 2008 | 9 | 12 |
| 2009 | 14 | 13 |
| 2010 | 9 | 14 |
| 2011 | 4 | 21 |
| 2012 | 11 | 18 |
| 2013 | 17 | 18 |
| 2014 | 26 | 22 |
| 2015 | 13 | 26 |
| 2016 | 20 | 29 |
| 2017 | 25 | 23 |
| 2018 | 18 | 26 |
| 2019 | 31 | 31 |
| 2020 | 19 | 28 |
| 2021 | 24 | 38 |
| 2022 | 20 | 27 |
| 2023 | 17 | 33 |
| 2024 | 18 | 31 |
| 2025 | 22 | 26 |
| 2026 | 14 | 30 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Psilocybin analogs, salts, compositions, and methods of use15 Sep 2026US 12,735,386 B2Cybin IRL Limited
- Salt forms of sabcomeline18 Aug 2026US 12,709,611 B2Syremis Therapeutics, Ltd.
- Cocrystalline forms of FGFR3 inhibitors23 Jun 2026US 12,662,483 B2Eli Lilly and Company
- Salt form and crystal form of pyrazole substituted imidazo[1,2-a]quinoxaline derivative9 Jun 2026US 12,649,747 B2Ocumension Therapeutics (Suzhou) Co., Ltd.
- Pharmaceutically acceptable salts of sepiapterin26 May 2026US 12,637,465 B2PTC Therapeutics MP, Inc.
- Cocrystalline forms of fgfr3 inhibitors1 Oct 2026US 2026/0297090 A1Eli Lilly and Company
- Salt form and crystal form of thienopyrimidine compound, and preparation method therefor and use thereof24 Sep 2026US 2026/0285874 A1Shandong Luye Pharmaceutical Co., Ltd.
- Psilocybin analogs, salts, compositions, and methods of use27 Aug 2026US 2026/0250246 A1Cybin IRL Limited
- Apoptosis inhibitor salts for cancer27 Aug 2026US 2026/0250269 A1
- Crystalline forms of tenofovir alafenamide6 Aug 2026US 2026/0226087 A1Gilead Sciences, Inc.
Most cited
By later US patents
- Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities164US 5,877,207 AAllergan Sales, Inc. · 1999
- Method of identifying negative hormone and/or antagonist activities151US 5,776,699 AAllergan, Inc. · 1998
- Bicyclic naphthalenic derivatives, a process for preparing the same and human or veterinary medicines and cosmetic compositions containing said derivatives142US 4,826,969 ACentre International de Recherches Dermatologiques (C.I.R.D.) · 1989
- Crystalline forms of a purine derivative99US 8,889,861 B2Cyclacel Limited · 2014
- Triarylethylene carboxylic acids with estrogenic activity91US 5,189,212 AUniversity of Georgia Research Foundation, Inc. · 1993